LOGIN  |  REGISTER
Recursion

Claritev’s PHCS Network Receives Twelfth Consecutive NCQA Accreditation in Credentialing

July 08, 2025 | Last Trade: US$29.20 0.00 0.00

MCLEAN, Va. / Jul 08, 2025 / Business Wire / Claritev Corporation (“Claritev” or the “Company”) (NYSE: CTEV) today announced that the PHCS Network, the largest primary PPO in the nation, received its 12th consecutive Accreditation in Credentialing from the National Committee for Quality Assurance (NCQA), a private nonprofit organization dedicated to improving health care quality. The PHCS Network is the only national independently contracted primary PPO with NCQA accreditation, demonstrating its unique commitment to the accurate and efficient credentialing of health care professionals.

First certified in 2001, the PHCS Network underwent a rigorous review of its credentialing and recredentialing processes to maintain its NCQA Accreditation in Credentialing. The network was reaccredited for the maximum period of 3 years, which is valid through June 13, 2028.

Through the accreditation process, the NCQA auditor specifically remarked that Claritev:

  • Had dedicated and knowledgeable staff,
  • Prepared files facilitating a smooth file review, and
  • Made timely credentialing decisions.

“This twelfth consecutive NCQA Accreditation is a testament to the unwavering commitment and caliber of our team to uphold the highest standards in credentialing,” said Jerry Hogge, Chief Operating Officer of Claritev. “It reflects our dedication to ensuring that healthcare professionals in the PHCS Network meet rigorous quality benchmarks, ultimately supporting better outcomes for the patients and partners we serve.”

The PHCS Network provides health plan members with seamless access to healthcare services across the country, with more than a million participating practitioners, 4,600 acute care facilities and 92,000 ancillaries.

About NCQA

NCQA accredits and certifies a wide range of health care organizations. It also recognizes clinicians and practices in key areas of performance. NCQA’s Healthcare Effectiveness Data and Information Set (HEDIS®) is the most widely used performance measurement tool in health care, with over 60% of the US population enrolled in health plans that use the measure. NCQA can be found online at ncqa.org, on Twitter @ncqa, on Facebook at facebook.com/NCQA.org/ and on LinkedIn at linkedin.com/company/ncqa.

NCQA has reviewed and accredited Claritev’s Credentialing functions for the PHCS Network only. For complete details on the scope of this review, visit www.ncqa.org.

About Claritev

Claritev, formerly known as MultiPlan, is a healthcare technology, data, and insights company focused on delivering affordability, transparency, and quality. Led by a team of deeply experienced associates, data scientists, and innovators, Claritev provides cutting-edge solutions and services fueled by multiple data sources and over 40 years of claims repricing experience. Claritev utilizes world-class technology and AI solutions to power a robust enterprise platform that delivers meaningful insights to drive affordability in healthcare, brings price transparency and optimizes networks and benefits design. By focusing on purpose–built solutions that support all key players – including payors, employers, patients, providers and third parties – Claritev aims to make healthcare more accessible and affordable for all. For more information, visit claritev.com.

Stock Quote

Featured Stock

ClearPoint Neuro

ClearPoint Neuro is a global therapy-enabling platform company providing stereotactic navigation and delivery to the brain. Applications of our ClearPoint Neuro Navigation System include electrode lead placement, placement of catheters, and biopsy. The platform has FDA clearance and is...

CLICK TO LEARN MORE

Featured Stock

C4 Therapeutics

C4 Therapeutics is pioneering a new class of small-molecule drugs that selectively destroy disease-causing proteins via degradation using the innate machinery of the cell. This targeted protein degradation approach offers advantages over traditional drugs, including the potential to treat a wider range of diseases...

CLICK TO LEARN MORE

End of content

No more pages to load

Next page